Fundraising FoxSoligenix
NASDAQ: SNGXPrinceton, US · Delaware corporation · 1 known investors
Find your way into Soligenix
Sign up to see every warm intro you have to Soligenix
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Soligenix team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Soligenix is a biopharmaceutical company developing treatments for rare diseases, with programs in photodynamic therapy for cutaneous T-cell lymphoma and psoriasis, immunomodulatory drugs for inflammatory conditions, and vaccine candidates for infectious diseases. The company operates through two segments: Specialized BioTherapeutics, focused on advancing HyBryte and related therapies toward commercialization, and Public Health Solutions, which develops vaccines and therapeutics supported primarily by government contracts.
Founders & leadership
Board
Investors · 1
How we know: Pontifax Venture Capital's portfolio page · the VCSheet dataset · Not right? Tell us
Reported raises · per SEC filings
Form D private placements$2M disclosed across 1 round · 2017
▶$2MraisedNov 2017 · 6 investors · PharmaceuticalsRule 506(b)
- Adam T. RumageExecutive Officer
- Richard C. Straube, MD MScExecutive Officer
- Karen KrumeichExecutive Officer
- Oreola Donini, PhDExecutive Officer
- Keith L. Brownlie, CPADirector
- Jerome B. Zeldis, PhDDirector
- Gregg A. LaPointe, CPADirector
- Robert J. Rubin, MDDirector
- R. Christopher Cavalli, PhDExecutive Officer
- Marco M. Brughera, DVMDirector
- Christopher J. Schaber, PhDExecutive Officer, Director
- Offering amount
- $2M
- Amount sold
- $2M
- Finders' fees
- $137.5K
- Placement agents
- Aegis Capital Corp.
- First sale
- Nov 2017
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Related companies · 1
Companies working in the same space as Soligenix.
Non-dilutive funding · 11 SBIR/STTR awards
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2021 | $1.5M |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2019 | $150K |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2017 | $1.5M |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2017 | $1.5M |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2014 | $300K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2014 | $225K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2012 | $600K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2012 | $300K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2009 | $509.9K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2006 | $470.5K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2003 | $149.9K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.
In the news
Frequently asked questions
- What does Soligenix do?
- Soligenix is a biopharmaceutical company developing treatments for rare diseases, with programs in photodynamic therapy for cutaneous T-cell lymphoma and psoriasis, immunomodulatory drugs for inflammatory conditions, and vaccine candidates for infectious diseases. The company operates through two segments: Specialized BioTherapeutics, focused on advancing HyBryte and related therapies toward commercialization, and Public Health Solutions, which develops vaccines and therapeutics supported primarily by government contracts.
- Who are Soligenix's investors?
- Soligenix's investors include Pontifax Venture Capital.
- How much funding has Soligenix raised?
- Soligenix has disclosed $2M raised across 1 round.
- Where is Soligenix headquartered?
- Soligenix is headquartered in Princeton, US.